SynthesisMedicine2025
Probiotics in nonsurgical treatment of peri-implant diseases: A systematic review & meta-analysis.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeri-implant disease is an inflammatory condition that affects implant stability and quality of life. As nonsurgical treatments show limited efficacy, probiotics have been explored for their anti-inflammatory effects. This systematic review evaluated the efficacy, safety, and health-related quality of life outcomes of peri-implant diseases.
methodsDatabases were searched for randomized controlled trials (RCTs) and non-randomized studies (November 2024). The outcomes included bleeding on probing (BoP), probing depth, plaque index, and biomarkers. The protocol was registered with International Prospective Register of Systematic Reviews (CRD42024617103). The RoB in RCTs was assessed using the Cochrane Risk of Bias 2.0 tool, and non-RCTs using the RoB In Non-randomized Studies of Interventions tool. Evidence certainty was graded using the Grading of Recommendations, Assessment framework.
resultsFourteen studies were included, and 10 RCTs (n = 391) were meta-analyzed. For peri-implant mucositis, probiotics reduced BoP at 3 months (mean difference [MD] -1.45; P = .002) and 6 months (MD -9.44; P = .0003) and improved plaque index at 3 months (MD -0.99; P = .001). No effects on probing depth or peri-implantitis were observed. Tumor necrosis factor-alpha levels improved, while interleukin levels remained unchanged. Microbial analysis revealed no major changes. Subgroup analyses showed greater effects in placebo-controlled versus active comparator studies. Health-related quality of life and long-term safety were not assessed. Evidence certainty ranged from moderate to very low.
conclusionProbiotics may provide modest short-term benefits for peri-implant mucositis by reducing BoP and plaque accumulation. Current evidence is insufficient to support its use in peri-implantitis or to establish long-term safety and patient-centered outcomes. Further high-quality long-term trials are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.